Monotherapy with P2Y12-inhibitors after dual antiplatelet therapy: Filling gaps in evidence
Int J Cardiol. 2024 Feb 19:131893. doi: 10.1016/j.ijcard.2024.131893. Online ahead of print. ABSTRACT BACKGROUND: Whether P2Y12 inhibitor monotherapy (P2Y12-I) is superior to aspirin following DAPT discontinuation post-PCI remains to be established. METHODS: We updated our prior network meta-analysis where P2Y12-I and aspirin had been compared with DAPT or directly with each other. The focus is…